NBIX Share Price

Open 43.75 Change Price %
High 44.99 1 Day 0.38 0.88
Low 42.85 1 Week -4.88 -10.06
Close 43.61 1 Month 2.26 5.47
Volume 1489609 1 Year -9.87 -18.46
52 Week High 57.82
52 Week Low 0.00
NBIX Important Levels
Resistance 2 45.59
Resistance 1 44.78
Pivot 43.82
Support 1 42.44
Support 2 41.63
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

NBIX Technical Analysis 3
As on 5th Dec 2016 NBIX Share Price closed @ 43.61 and we RECOMMEND Sell for LONG-TERM with Stoploss of 45.56 & Sell for SHORT-TERM with Stoploss of 48.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
NBIX Target for December
1st Target up-side 54.63
2nd Target up-side 60.36
3rd Target up-side 66.09
1st Target down-side 38.28
2nd Target down-side 32.55
3rd Target down-side 26.82
NBIX Other Details
Segment EQ
Market Capital 483944384.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.neurocrine.com
NBIX Address
NBIX
12780 El Camino Real
San Diego, CA 92130
United States
Phone: 858-617-7600
Fax: 858-617-7601
Interactive Technical Analysis Chart Neurocrine Biosciences, Inc. ( NBIX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neurocrine Biosciences, Inc.
NBIX Business Profile
Neurocrine Biosciences, Inc. (Neurocrine) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company�s product candidates address some of the pharmaceutical markets including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine has 11 programs in various stages of research and development, including six programs in clinical development. It has entered into collaborations for six of its programs. Its lead clinical development program, elagolix, is a drug candidate for the treatment of endometriosis. The Company�s product portfolio include Elagolix, Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), CRF2 Peptide Agonist-urocortin 2, CRF1 Antagonist (561679), CRF1 Antagonist (586529), G Protein-Coupled Receptor 119 (GPR119), VMAT2, GnRH Antagonists, Antiepileptic Drugs, G Protein-Coupled Receptors and Indiplon.